Northwest Biotherapeutics, Inc. (NWBO)
NWBO Stock Price Chart
Explore Northwest Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze NWBO price movements and trends.
NWBO Company Profile
Discover essential business fundamentals and corporate details for Northwest Biotherapeutics, Inc. (NWBO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Dec 2001
Employees
25.00
Website
https://www.nwbio.comCEO
Linda F. Powers
Description
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
NWBO Financial Timeline
Browse a chronological timeline of Northwest Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 14 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$0.01 , while revenue for the quarter reached $131.00K .
Earnings released on 15 May 2025
EPS came in at -$0.01 , while revenue for the quarter reached $375.00K .
Earnings released on 31 Mar 2025
EPS came in at -$0.02 , while revenue for the quarter reached $231.00K .
Earnings released on 12 Nov 2024
EPS came in at -$0.02 , while revenue for the quarter reached $357.00K .
Earnings released on 9 Aug 2024
EPS came in at -$0.02 , while revenue for the quarter reached $510.00K , missing expectations by -99.96%.
Earnings released on 10 May 2024
EPS came in at -$0.02 , while revenue for the quarter reached $284.00K , missing expectations by -99.98%.
Earnings released on 5 Mar 2024
EPS came in at -$0.02 , while revenue for the quarter reached $445.00K , missing expectations by -99.97%.
Earnings released on 9 Nov 2023
EPS came in at -$0.02 , while revenue for the quarter reached $406.00K , missing expectations by -99.97%.
Earnings released on 9 Aug 2023
EPS came in at -$0.01 , while revenue for the quarter reached $201.00K .
Earnings released on 10 May 2023
EPS came in at -$0.01 , while revenue for the quarter reached $880.00K .
Earnings released on 28 Feb 2023
EPS came in at -$0.03 , while revenue for the quarter reached $597.00K .
Earnings released on 9 Nov 2022
EPS came in at -$0.03 , while revenue for the quarter reached $206.00K .
Earnings released on 9 Aug 2022
EPS came in at -$0.03 , while revenue for the quarter reached $477.00K .
Earnings released on 9 May 2022
EPS came in at -$0.01 , while revenue for the quarter reached $403.00K .
Earnings released on 1 Mar 2022
EPS came in at $0.14 , while revenue for the quarter reached -$1.01M .
Earnings released on 15 Nov 2021
EPS came in at $0.04 , while revenue for the quarter reached $350.00K .
Earnings released on 16 Aug 2021
EPS came in at -$0.01 , while revenue for the quarter reached $416.00K .
Earnings released on 17 May 2021
EPS came in at -$0.00 , while revenue for the quarter reached $239.00K .
Earnings released on 31 Mar 2021
EPS came in at -$0.34 , while revenue for the quarter reached $503.00K .
Earnings released on 15 Jan 2021
EPS came in at -$0.07 , while revenue for the quarter reached $216.00K .
NWBO Stock Performance
Access detailed NWBO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.